Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 19, Issue 4, Pages 243-245
http://dx.doi.org/10.1155/2012/841530
Clinico-Pathologic Conferences

Pulmonary Alveolar Proteinosis

Sandeep M Patel,1 Hiroshi Sekiguchi,2 Jordan P Reynolds,3 and Michael J Krowka2

1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
2Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are predominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the understanding of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor antibodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing awareness among physicians when treating patients who present with alveolar infiltrates.